C4 Therapeutics (CCCC) Non-Current Deffered Revenue (2019 - 2026)

C4 Therapeutics' Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $15.4 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 38.53% year-over-year to $15.4 million in Q1 2026; TTM through Mar 2026 was $15.4 million, a 38.53% decrease from a year earlier, with the FY2025 full-year figure at $15.8 million, down 44.33% from the prior year.
• Non-Current Deffered Revenue declined to $15.4 million in Q1 2026 per CCCC's latest filing, from $15.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $28.6 million in Q3 2024 and bottomed at $15.4 million in Q1 2026.
• The 5-year median for Non-Current Deffered Revenue is $19.6 million (2023), against an average of $20.3 million.
• Across the five-year window, Non-Current Deffered Revenue sank 62.62% in 2022 and soared 45.99% in 2024, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $16.9 million in 2022, then increased by 29.12% to $21.8 million in 2023, then soared by 30.45% to $28.5 million in 2024, then slumped by 44.33% to $15.8 million in 2025, then slipped by 2.53% to $15.4 million in 2026.
• Per Business Quant, the three latest CCCC Non-Current Deffered Revenue figures stand at $15.4 million (Q1 2026), $15.8 million (Q4 2025), and $19.9 million (Q3 2025).